A Phase I/II Trial Of OSI-774 [erlotinib] In Patients With Recurrent Malignant Gliomas And Malignant Gliomas Post Radiation Therapy.

Trial Profile

A Phase I/II Trial Of OSI-774 [erlotinib] In Patients With Recurrent Malignant Gliomas And Malignant Gliomas Post Radiation Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Meningioma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top